About Anika Therapeutics Inc. - Common Stock (ANIK)
Anika Therapeutics is a biotechnology company that specializes in developing and commercializing innovative therapeutic solutions to treat musculoskeletal diseases and conditions. The company focuses on leveraging its expertise in glycosaminoglycan-based therapies to create advanced products for joint preservation, pain management, and surgical recovery. Anika's portfolio includes a range of orthopedic and surgical products aimed at improving patient outcomes and enhancing quality of life for individuals suffering from joint-related ailments. By combining scientific research with cutting-edge technology, Anika strives to address unmet medical needs in the field of orthopedics. Read More
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ:ANIK). The investigation concerns whether Anika and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ: ANIK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the pre-specified co-primary endpoints of percent change in KOOS Pain and IKDC function
BEDFORD, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter 2025 financial results before the opening of the market on Wednesday, July 30, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
BEDFORD, Mass., July 03, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on July 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $10.53, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.
BEDFORD, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on June 2, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $11.45, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.
BEDFORD, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on May 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 5,000 shares of common stock at a per share exercise price of $14.46, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to two newly hired non-executive employees. The grants were made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, were approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), were made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.
BEDFORD, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that management will participate in the Sidoti Virtual Investor Conference on Wednesday, May 21, 2025. Anika will host a virtual presentation with Q&A starting at 1:00pm ET.
BEDFORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2025 financial results before the opening of the market on Friday, May 9, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
BEDFORD, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the Osteoarthritis (“OA”) Pain Management and Regenerative Solutions space focused on early intervention orthopedics, today announced that on April 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 3,800 shares of common stock at a per share exercise price of $15.03, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.
BEDFORD, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2024 financial results after the close of the market on Wednesday, March 12, 2025 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
BEDFORD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and CEO of Anika, will present at the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego on Monday, March 10, 2025 at 2:30pm PT / 5:30pm ET. Management will also participate in one-on-one investor meetings throughout the event.
BEDFORD, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and CEO of Anika, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2025 at 9:45am PT / 12:45pm ET. Management will also participate in one-on-one investor meetings throughout the event.
BEDFORD, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that senior management will participate in the following upcoming conferences.
